All In Biotech

Drug Trial Radar · NCT05873803

The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

A Randomized, Double Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety of GR1802 Injection in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Last checked: Nov 19, 2026Latest source record: Sep 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

70

Planned (sponsor's estimate)

Start

Feb 8, 2023

Primary completion

Oct 30, 2024

Study completion Dec 30, 2024

Sponsor

Sponsor type
Industry
First posted
May 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in addition to a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Patients will receive GR1802 injection or Placebo every 2 Weeks.

Conditions

  • Chronic Rhinosinusitis with Nasal Polyps

Interventions

  • GR1802 injectionBiological

    150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

  • placeboBiological

    0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline at Week 16 in Nasal Congestion/Obstruction Symptom(NCS) Severity ScoreTime frame: at Week 16
  2. Change From Baseline at Week 16 in Nasal Polyp ScoreTime frame: at Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.